<DOC>
	<DOCNO>NCT01542866</DOCNO>
	<brief_summary>This prospective pilot study evaluate usability applicability self monitor test visual function handheld Health Management Tool ( HMT ) remotely monitor neovascular Age Related Macular Degeneration ( AMD ) detect potential change disease status .</brief_summary>
	<brief_title>A 16 Week Evaluation Novartis Health Management Tool ( HMT ) Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients CNV secondary AMD cause least one eye identify investigator eligible ranibizumab treatment Patients BCVA letter score study eye 24 good use ETDRS chart measure 4 meter distance Patients concurrent ocular condition may result visual loss study Patients past ( within prior 6 month ) current use , likely need , systemic medication know toxic lens , retina , optic nerve Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>Age relate Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Health Management Tool</keyword>
	<keyword>HMT</keyword>
	<keyword>Best Corrected Visual Acuity</keyword>
	<keyword>Investigator 's Clinical Judgement Change</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Central Retinal Subfield Thickness</keyword>
	<keyword>visual function self test</keyword>
</DOC>